Related by context. All words. (Click for frequent words.) 79 docetaxel 77 gemcitabine 76 erlotinib 75 bortezomib 74 bevacizumab 74 rituximab 73 topotecan 73 cetuximab 72 cisplatin 72 pemetrexed 72 imatinib 72 lapatinib 72 capecitabine 71 sorafenib 71 Taxotere 71 sunitinib 71 pegylated liposomal doxorubicin 71 HER2 positive metastatic breast 70 FOLFOX 70 gefitinib 70 adjuvant therapy 70 temozolomide 70 neoadjuvant chemotherapy 70 doxorubicin 70 decitabine 69 Taxotere ® 69 carboplatin paclitaxel 69 metastatic renal cell carcinoma 69 5FU 69 Fludara 69 mitoxantrone 69 chlorambucil 69 paclitaxel 69 zoledronic acid 69 FOLFOX4 69 azacitidine 68 temsirolimus 68 docetaxel chemotherapy 68 cyclophosphamide 68 tamoxifen 68 dacarbazine 68 letrozole 68 5 FU 68 adjuvant chemotherapy 68 Trastuzumab 68 pertuzumab 68 irinotecan 68 epirubicin 68 bevacizumab Avastin 67 oxaliplatin 67 dasatinib 67 carboplatin 67 FOLFIRI 67 trabectedin 67 Herceptin 67 mRCC 67 vandetanib 67 peginterferon 67 fluorouracil 67 lamivudine 67 chemoradiation 67 TACE 66 anastrozole 66 etoposide 66 sorafenib Nexavar 66 fludarabine 66 Herceptin trastuzumab 66 Doxil ® 66 neoadjuvant 66 trastuzumab Herceptin 66 chemoradiotherapy 66 XELOX 66 relapsed ovarian cancer 66 Femara 66 5 fluorouracil 66 mycophenolate mofetil 66 ixabepilone 66 aromatase inhibitor 65 pomalidomide 65 panitumumab 65 tamoxifen therapy 65 hormonal therapy 65 gemcitabine carboplatin 65 APTIVUS r 65 DMARD 65 azathioprine 65 monotherapy 65 plus dexamethasone 65 metastatic breast cancer 65 interferon alfa 65 mapatumumab 65 G CSF 65 gemcitabine chemotherapy 65 chemotherapy regimens 65 virologic failure 65 free survival PFS 65 T DM1 65 lenalidomide 65 erlotinib Tarceva ® 65 exemestane 65 interferon alfa 2a 65 neoadjuvant therapy 65 heavily pretreated patients 65 nab paclitaxel 65 bevacizumab Avastin ® 65 adalimumab 65 metastatic RCC 65 docetaxel Taxotere 65 iniparib 64 idarubicin 64 axitinib 64 vinorelbine 64 imatinib Gleevec 64 interferon 64 raltegravir 64 advanced NSCLC 64 cabazitaxel 64 methotrexate 64 cisplatin chemotherapy 64 pegylated interferon 64 Gemcitabine 64 chemotherapeutic agents 64 Vectibix 64 Tykerb 64 nilotinib 64 tocilizumab 64 dose cytarabine 64 chemotherapy regimen 64 Doxil 64 letrozole Femara 64 anthracycline 64 Erlotinib 64 HER2 positive breast cancer 64 imetelstat 64 fulvestrant 64 gemcitabine Gemzar 64 standard chemotherapy regimen 64 NRTIs 64 low dose cytarabine 64 Xeloda 64 lapatinib Tykerb 64 bendamustine 64 Targretin 64 metformin 64 daunorubicin 63 adjuvant radiation 63 cytarabine 63 Bevacizumab 63 nelfinavir 63 clopidogrel 63 bicalutamide 63 pCR 63 EBRT 63 gefitinib Iressa 63 chemotherapeutic agent 63 sipuleucel T 63 anthracyclines 63 metastatic colorectal cancer 63 anti TNF 63 DMARDs 63 brain metastases 63 etanercept 63 Tarceva 63 endocrine therapy 63 CANCIDAS 63 tyrosine kinase inhibitor 63 Cisplatin 63 Imprime PGG 63 tyrosine kinase inhibitors 63 preoperative chemotherapy 63 chemotherapies 63 YONDELIS 63 trastuzumab Herceptin ® 63 Taxotere R 63 Velcade bortezomib 63 EGFR TKI 63 HER2 63 Torisel 63 enfuvirtide 63 taxane 63 pegylated interferon alfa 2b 63 ritonavir boosted 63 VIDAZA 63 Rituxan 63 EGFR tyrosine kinase inhibitors 63 taxanes 62 Bortezomib 62 chronic lymphocytic leukemia CLL 62 cytotoxic chemotherapy 62 insulin glargine 62 mCRC patients 62 HRPC 62 allogeneic SCT 62 Platinol 62 oblimersen 62 DAPT 62 EGFR inhibitors 62 abiraterone acetate 62 5-FU/LV 62 tipranavir 62 taxane therapy 62 goserelin 62 protease inhibitor 62 cetuximab Erbitux R 62 afatinib 62 Irinotecan 62 paclitaxel Taxol 62 HER2 positive 62 interferon alpha 62 clodronate 62 CsA 62 low dose dexamethasone 62 fondaparinux 62 entecavir 62 NNRTI 62 posaconazole 62 NSCLC 62 capecitabine Xeloda 62 anthracycline taxane 62 sunitinib malate 62 melphalan prednisone 62 plus prednisone 62 SCCHN 62 enzastaurin 62 anti leukemic 62 heavily pretreated 62 FOLFOX6 62 abiraterone 62 TYKERB 62 recurrent GBM 62 dose dexamethasone 62 rituximab Rituxan 62 5 Fluorouracil 62 EpCAM 62 Cytoxan 62 sorafenib Nexavar ® 62 pazopanib 62 infliximab 62 seliciclib 62 intravenous bisphosphonates 62 imatinib therapy 62 CHOP chemotherapy 62 Peg IFN 62 pioglitazone 62 EGFR mutations 62 Folfox 62 adecatumumab 62 GnRH agonists 61 thalidomide Thalomid 61 teriflunomide 61 ribavirin RBV 61 pamidronate 61 eptifibatide 61 standard chemotherapy regimens 61 fluoropyrimidine 61 hormone refractory prostate cancer 61 cyclophosphamide methotrexate 61 IFN α 61 PXD# 61 pancreatic adenocarcinoma 61 tanespimycin 61 median PFS 61 immunosuppressant 61 Revlimid lenalidomide 61 adriamycin 61 metastatic castration resistant 61 abacavir lamivudine 61 peginterferon alfa 2a 61 vorinostat 61 sustained virologic response 61 Tarceva TM 61 HER2 negative 61 trastuzumab Herceptin R 61 3TC lamivudine Epivir 61 xenograft models 61 Lapatinib 61 idraparinux 61 chemotherapy docetaxel 61 Cetuximab 61 INTELENCE 61 talabostat 61 resistant ovarian cancer 61 cetuximab Erbitux ® 61 Gleevec 61 paclitaxel chemotherapy 61 VICTRELIS 61 IFN alpha 61 adefovir 61 KRAS mutations 61 OncoVEX GM CSF 61 infusional 5-FU/LV 61 dexamethasone Decadron 61 liposomal doxorubicin 61 Capecitabine 61 metastatic disease 61 glatiramer acetate 61 gemcitabine cisplatin 61 antitumor activity 61 androgen deprivation 61 risedronate 61 taxane chemotherapy 61 EGFR mutation 61 postoperative chemotherapy 61 Neoadjuvant 61 Bezielle 61 platinum refractory 61 TNF inhibitors 61 mCRC 61 TNF inhibitor 61 KRAS status 60 ipilimumab 60 Vidaza 60 dasatinib Sprycel 60 plus ribavirin 60 NNRTIs 60 vicriviroc 60 TORISEL 60 docetaxel prednisone 60 MGd 60 Gemzar ® 60 temozolomide TMZ 60 oral clodronate 60 pegylated interferon alfa 60 LEXIVA r 60 lopinavir r 60 ribavirin 60 chemotherapy gemcitabine 60 mg kg dose 60 peginterferon alfa 2b 60 anti EGFR antibody 60 KRAS mutant tumors 60 telaprevir dosed 60 Lenalidomide 60 T#I [002] 60 dexamethasone 60 FOLPI 60 comparator arm 60 K ras mutations 60 cilengitide 60 everolimus 60 erlotinib Tarceva 60 docetaxel Taxotere ® 60 melphalan 60 metastatic CRC 60 aflibercept 60 EGFR 60 Dasatinib 60 darunavir 60 biologic therapy 60 ARIMIDEX 60 IRESSA 60 Aromasin 60 CD# antibody [001] 60 chemotherapy 60 depsipeptide 60 CMV disease 60 PegIFN RBV 60 Kaplan Meier analysis 60 mitomycin 60 paclitaxel carboplatin 60 Hycamtin 60 GRN#L 60 abciximab 60 perifosine 60 Zolinza 60 VELCADE 60 ibandronate 60 eribulin 60 imipenem 60 DOXIL 60 EGFr 60 epirubicin cyclophosphamide 60 relapsing multiple sclerosis 60 INCB# [001] 60 clopidogrel Plavix 60 irinotecan chemotherapy 60 placebo dexamethasone 60 Elitek 60 Amrubicin 60 Taxotere chemotherapy 60 FluCAM 60 disease progression 60 fluvastatin 60 androgen independent 60 adjuvant radiotherapy 60 peginterferon alfa 2a Pegasys 60 celecoxib 60 darunavir ritonavir 60 pegfilgrastim 60 YERVOY 60 anakinra 60 cyclophosphamide Cytoxan 60 BAY #-# 60 calcitriol 60 irbesartan 60 LMWH 60 AZT zidovudine Retrovir 60 docetaxel Taxotere R 60 tamsulosin 60 pegylated interferon alpha 60 Avastin 60 recurrent NSCLC 60 Gefitinib 60 refractory multiple myeloma 60 imatinib mesylate Gleevec 60 relapsed MM 60 chemotherapeutic regimen 60 CYC# 60 tumor recurrence 60 Velcade 60 KRAS mutation 60 VELCADE melphalan 60 peg IFN 60 PREZISTA r 60 SCH # 60 diagnosed multiple myeloma 60 Jevtana 60 interferon IFN 60 methotrexate therapy 60 prostate cancer CRPC 60 APTIVUS 60 dacetuzumab 60 NRTI 59 Avastin bevacizumab 59 PREZISTA rtv 59 neoadjuvant treatment 59 CoFactor 59 active comparator 59 castration resistant prostate cancer 59 Rituximab 59 plus gemcitabine 59 Ceplene/IL-2 59 abatacept 59 CIMZIA ™ 59 ZOLINZA 59 octreotide LAR 59 cediranib 59 HER2 + 59 cetuximab Erbitux 59 sustained virological response 59 Traficet EN 59 interferon alfa 2b 59 chemotherapy FOLFOX 59 Mylotarg 59 alteplase 59 ISENTRESS 59 oxaliplatin Eloxatin 59 liver metastases 59 CIMZIA TM 59 relapsed SCLC 59 Telintra 59 Zometa 59 platelet reactivity 59 antiplatelet therapy 59 paclitaxel Taxol ® 59 alkylating agent 59 nitazoxanide 59 adalimumab Humira 59 Taxotere docetaxel 59 valsartan 59 IMGN# 59 chemotherapy cisplatin 59 HuMax CD4 59 glufosfamide 59 epoetin 59 dasatinib Sprycel ® 59 boosted protease inhibitor 59 virologic response 59 antithrombotic 59 recurrent ovarian cancer 59 prostate cancer HRPC 59 PegIntron 59 gp# vaccine 59 ABVD 59 uric acid lowering 59 antiangiogenic 59 thymalfasin 59 Halaven 59 leucovorin 59 natalizumab 59 zalutumumab 59 GVAX 59 efavirenz Sustiva 59 fluconazole 59 FUZEON 59 galiximab 59 chemotherapeutic drug 59 epoetin beta 59 zidovudine 59 TEMODAL 59 Symadex 59 bivalirudin 59 exemestane Aromasin 59 Aptivus ® 59 Adriamycin 59 ERCC1 59 adjuvant tamoxifen 59 neurologic progression 59 olmesartan 59 OPAXIO 59 NEUVENGE 59 3TC 59 Pemetrexed 59 SUTENT 59 allopurinol 59 HSCT 59 protease inhibitor PI 59 receiving VICTRELIS 59 regorafenib 59 antiangiogenic therapy 59 paricalcitol 59 Hycamtin ® 59 mTOR inhibitor 59 estramustine 59 distant metastasis 59 Taxol 59 TAXOTERE R 59 locoregional 59 refractory AML 59 HAART regimens 59 chemotherapeutic regimens 59 lopinavir 59 Pegasys ® 59 ErbB2 positive 59 tirofiban 59 Paraplatin ® 59 EGF receptor 59 IMC A# 59 calcineurin inhibitors 59 ASA# 59 Fludarabine 59 angiogenesis inhibitor 59 EFAPROXYN 59 pemetrexed Alimta 59 bone metastasis 59 Telcyta 59 KRAS wild 59 amrubicin 59 mcg kg 59 milatuzumab 59 valopicitabine 59 antiandrogen 59 5 FU leucovorin 59 Sandostatin LAR 59 fibrinolytic 58 Natalizumab 58 Dacogen 58 follicular NHL 58 metastatic prostate cancer 58 anti androgen 58 oral Xeloda 58 nucleoside analog 58 BRAF mutation 58 mTOR inhibitors 58 PARP inhibitor 58 Taxol paclitaxel 58 rivaroxaban 58 mutated KRAS 58 virologic 58 IFN beta 58 panitumumab Vectibix 58 AVASTIN 58 sorafenib tablets 58 ELOXATIN 58 Tarceva erlotinib 58 PSMA ADC 58 Genasense 58 Faslodex 58 complete remissions 58 EGFR TKIs 58 imatinib Gleevec ® 58 amlodipine 58 protease inhibitors 58 TroVax ® 58 LY# [003] 58 eplerenone 58 Laquinimod 58 ovarian carcinoma 58 DFMO 58 HAART 58 iodixanol 58 distant metastases 58 neratinib 58 paclitaxel Taxol R 58 atazanavir 58 KRAS mutations occur 58 tesmilifene 58 interferon ribavirin 58 Imatinib 58 colorectal liver metastases 58 custirsen 58 alemtuzumab 58 LPV r 58 ceftriaxone 58 pralatrexate 58 stage IIIB 58 cytotoxic therapy 58 TroVax 58 pegylated interferon alfa 2a 58 PLX# 58 GnRH agonist 58 trans retinoic acid 58 relapsed refractory multiple myeloma 58 noninferiority 58 aprepitant 58 viral kinetics 58 ramipril 58 interferon gamma 1b 58 IRX 2 58 hepatocellular carcinoma HCC 58 gastrointestinal stromal tumors GIST 58 Navelbine 58 Ixempra 58 factor G CSF 58 enoxaparin 58 Erbitux 58 Fludara ® 58 Arixtra 58 interferon therapy 58 genotypic resistance 58 Panitumumab 58 MabThera 58 HGS# 58 alfa 2a 58 metastatic HRPC 58 TNF α 58 unresectable 58 dacarbazine chemotherapy 58 CR nPR 58 teriparatide 58 Tavocept 58 biochemical recurrence 58 MabCampath 58 Pertuzumab 58 prostate cancer AIPC 58 chemoradiation therapy 58 HGS ETR2 58 tumor shrinkage 58 Exemestane 58 hormone receptor positive 58 elacytarabine 58 tenofovir emtricitabine 58 lenalidomide Revlimid R 58 Platinol ® cisplatin 58 biochemical relapse 58 anticancer therapy 58 Eli Lilly Gemzar 58 relapsed refractory 58 aromatase inhibitors 58 administered subcutaneously 58 belinostat 58 ZD# [001] 58 alpha interferon 58 Pegylated Interferon 58 recurrent glioblastoma multiforme 58 Cloretazine 58 boceprevir 58 LHRH agonist 58 breast carcinoma 58 Peginterferon 58 bevacizumab Avastin R 58 APOPTONE 58 flutamide 58 metastatic hormone refractory 58 leukemia AML 58 FIRMAGON 58 nucleoside analogue 58 IGF 1R 58 Flu Cy 58 anthracycline containing 58 ritonavir 58 taxane refractory 58 cinacalcet 58 Camptosar 58 alendronate 58 relapsed myeloma 58 tipranavir ritonavir 58 WBRT 57 tiotropium 57 epoetin alfa 57 ISF# 57 doxorubicin HCl liposome injection 57 somatostatin analogue 57 PCa 57 imatinib resistant 57 bone metastases 57 Revlimid 57 Sym# 57 elotuzumab 57 panobinostat 57 peg interferon 57 Alkeran 57 oral allopurinol 57 CellCept 57 metastatic GIST 57 obatoclax 57 partial remissions 57 lymphadenectomy 57 mcg albinterferon alfa 2b 57 metastatic colon cancer 57 TELCYTA 57 evaluating tivozanib 57 relapsed multiple myeloma 57 Gleevec resistant 57 Xanafide 57 mcg dose 57 FTY# 57 MGCD# [001] 57 BRAF inhibitor 57 operable breast cancer 57 CRp 57 metastatic malignant 57 surrogate endpoint 57 LHRH 57 octreotide 57 ASCT 57 IFN alfa 57 receptor tyrosine kinase inhibitor 57 Camptosar ® 57 Docetaxel 57 cisplatin vinorelbine 57 oral antidiabetic 57 hormonal therapies 57 durable remissions 57 HBeAg positive patients 57 CR# vcMMAE 57 Nexavar 57 TMC# [001] 57 refractory ovarian cancer 57 androgen suppression 57 #mg/m# [001] 57 external beam radiotherapy 57 crizotinib PF # 57 locoregional recurrence 57 unfractionated heparin 57 luteinizing hormone releasing 57 Ontak 57 MetMAb 57 ganetespib 57 FOLFIRI alone 57 sunitinib Sutent ® 57 basal cell carcinoma BCC 57 bosentan 57 bortezomib Velcade R 57 chemotherapeutic 57 VAPRISOL 57 maraviroc 57 comparator PI r 57 immunomodulatory 57 assessing T DM1 57 IV bisphosphonates 57 cART 57 interferon beta 57 dutasteride 57 VEGFR2 57 capecitabine Xeloda R 57 Temozolomide 57 therapeutic regimens 57 STELARA 57 fosamprenavir 57 alpha 2a 57 TKI therapy 57 ticagrelor 57 Adjuvant chemotherapy 57 adjuvant 57 endometrial hyperplasia 57 antidiabetic 57 doxorubicin docetaxel 57 leukemia CLL 57 Sorafenib 57 angiotensin receptor blocker ARB 57 lupus nephritis 57 insulin detemir 57 alkylating agents 57 molecularly targeted 57 gemcitabine Gemzar ® 57 non squamous NSCLC 57 immunomodulator 57 Proxinium TM 57 eribulin mesylate 57 sapacitabine 57 remission CR 57 CA4P 57 bisphosphonates 57 huN# DM1 57 integrase inhibitor 57 VEGF inhibitors 57 Epivir 57 refractory CLL 57 lumbar spine BMD 57 omalizumab 57 tenofovir Viread 57 AP# [003] 57 voriconazole 57 Vectibix monotherapy 57 mg BID 57 ofatumumab 57 GM CSF 57 clusterin 57 GP IIb IIIa inhibitors 57 hydroxyurea 57 zoledronic acid Zometa 57 Azixa 57 azacytidine 57 piperacillin tazobactam 57 HER2 positive tumors 57 achieved ACR# 57 methotrexate MTX 57 moxifloxacin 57 APTIVUS R 57 lenalidomide dexamethasone 57 Gemzar 57 hepatic metastases 57 methotrexate monotherapy 57 HER2 overexpression 57 Gleevec imatinib 57 immunosuppressive agents 57 Interferon alfa 57 HER2/neu 57 efalizumab 57 losartan 57 DAVANAT 57 vincristine doxorubicin 57 figitumumab 57 complete cytogenetic response 57 REYATAZ R 57 overlapping toxicities 57 evaluable patients 57 Median progression 57 gastrointestinal stromal tumor GIST 57 bleomycin 57 olaparib 57 NeoRecormon 57 ACZ# 57 romiplostim 57 Caelyx 57 MyVax R 57 epithelial ovarian cancer 57 Taxol ® 57 nucleoside analogues 57 TOP2A 57 belimumab 57 Neulasta ® 57 Allovectin 7 ® 57 HSP# inhibitor 57 palifosfamide 57 belatacept 57 BRIM2 57 levosimendan 57 chemotherapeutics 57 ACE inhibitor 57 aromatase inhibitor therapy 57 sirolimus eluting stent 57 platelet inhibitor 57 Seliciclib 57 stavudine d4T 57 atrasentan 57 evaluable 57 HBeAg seroconversion 57 Reverset 57 pyrazinamide 57 renal cell carcinoma 56 Hazard Ratio 56 Femara letrozole 56 Adalimumab 56 pan HDAC inhibitor 56 adjuvant endocrine therapy 56 Sanofi Aventis Taxotere 56 endocrine therapies 56 rt PA 56 ALND 56 ACTEMRA 56 EGFRvIII 56 lipid lowering therapy 56 progression TTP 56 proteasome inhibitor 56 IGF IR 56 allogeneic stem cell 56 HGS ETR1 56 metastatic melanoma 56 doxorubicin cyclophosphamide 56 Pegasys plus Copegus 56 breast cancer recurrence 56 AEGR 56 advanced adenomas 56 CAELYX 56 xanthine oxidase inhibitor 56 sirolimus 56 anti TNFs 56 pegylated interferons 56 adjuvant trastuzumab 56 glargine 56 Recurrence Score 56 strontium ranelate 56 SPRYCEL 56 Bevacizumab Avastin 56 metastatic lung cancer 56 oral chemotherapeutic agent 56 Zevalin consolidation 56 tumor progression 56 RG# [001] 56 B CLL 56 superficial bladder cancer 56 micrometastases 56 FOLOTYN 56 HCV 56 NNRTI resistance 56 Tamibarotene 56 daclizumab 56 Gleevec imatinib mesylate 56 ZACTIMA 56 antibody MAb 56 Median survival 56 Cremophor 56 dosage regimens 56 subcutaneously administered 56 Boceprevir 56 Campath alemtuzumab 56 sitagliptin 56 severe neutropenia 56 bortezomib Velcade 56 HAART regimen 56 plasma uric acid 56 Copegus ribavirin 56 Erbitux cetuximab 56 Everolimus 56 metastatic malignant melanoma 56 autologous stem cell 56 HER2 receptor 56 amoxicillin clavulanate 56 debulking surgery 56 antiretroviral regimen 56 MAGE A3 ASCI 56 Platinol ® 56 hA# 56 ERBITUX 56 EndoTAGTM 1 56 FLT3 56 NMIBC 56 androgen deprivation therapy 56 REBETOL 56 Azedra 56 statin 56 bezafibrate 56 folinic acid 56 concurrent chemoradiation 56 BEACOPP 56 PKC# 56 ISTODAX 56 ACTEMRA TM 56 ELACYT 56 ATACAND 56 Aflibercept 56 antiviral therapy 56 phenoxodiol 56 lipid lowering therapies 56 anti TNF alpha 56 HIV RNA 56 liposomal amphotericin B 56 XmAb# 56 cytotoxicity 56 lung metastases 56 bevacizumab Avastin Genentech 56 paclitaxel poliglumex 56 prostate cancer mCRPC 56 peginterferon alfa 56 SABCS 56 paclitaxel eluting stents 56 adenoma recurrence 56 picoplatin 56 EZN 56 5 fluorouracil leucovorin 56 Amigal 56 nilotinib Tasigna ® 56 entinostat 56 Tamoxifen 56 PSADT 56 atazanavir ritonavir 56 tacrolimus 56 tamoxifen Nolvadex ® 56 estrogen therapy 56 HuLuc# 56 cilostazol 56 Anthracycline 56 REVLIMID 56 PROSTVAC TM 56 romidepsin 56 saline placebo 56 adjuvant therapies 56 cobicistat 56 CCX# 56 ximelagatran 56 metastatic renal cell 56 iclaprim 56 Sutent 56 TDF FTC 56 weekly subcutaneous injections 56 HBeAg negative patients 56 FOLFOX chemotherapy